Congratulations Dr. Shami
Sep 25, 2017 9:00 AM
Dr. Paul Shami and JSK Therapeutics were granted an award from the Small Business Innovation Research Program of the National Cancer Institute to conduct IND-enabling studies of their nitric oxide-generating drug JS-K. JS-K has shown efficacy in animal models of acute myeloid leukemia, multiple myeloma, non-small cell lung cancer and several other solid tumors. Completion of work conducted with this award will allow initiation of Phase I clinical trials of this first-in-class anti-cancer agent. Congratulations to Dr. Shami and his team for this Direct-to-Phase II SBIR award.